KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardlytics (CDLX) Change in Accured Expenses (2017 - 2025)

Historic Change in Accured Expenses for Cardlytics (CDLX) over the last 9 years, with Q3 2025 value amounting to $842000.0.

  • Cardlytics' Change in Accured Expenses fell 7926.62% to $842000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 32039.8%. This contributed to the annual value of -$6.6 million for FY2024, which is 1131.87% up from last year.
  • Per Cardlytics' latest filing, its Change in Accured Expenses stood at $842000.0 for Q3 2025, which was down 7926.62% from -$975000.0 recorded in Q2 2025.
  • In the past 5 years, Cardlytics' Change in Accured Expenses ranged from a high of $5.8 million in Q2 2022 and a low of -$11.6 million during Q1 2022
  • Its 5-year average for Change in Accured Expenses is -$1.2 million, with a median of $381000.0 in 2024.
  • In the last 5 years, Cardlytics' Change in Accured Expenses crashed by 921176.47% in 2021 and then skyrocketed by 162727.27% in 2023.
  • Over the past 5 years, Cardlytics' Change in Accured Expenses (Quarter) stood at $1.7 million in 2021, then tumbled by 315.11% to -$3.7 million in 2022, then skyrocketed by 175.36% to $2.8 million in 2023, then tumbled by 223.73% to -$3.5 million in 2024, then surged by 124.39% to $842000.0 in 2025.
  • Its Change in Accured Expenses was $842000.0 in Q3 2025, compared to -$975000.0 in Q2 2025 and $1.9 million in Q1 2025.